Published in J Immunol on September 15, 2010
Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet (2011) 1.84
Aicardi-Goutières syndrome and the type I interferonopathies. Nat Rev Immunol (2015) 1.82
Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. J Immunol (2012) 1.57
Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol (2012) 1.44
Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res (2011) 1.18
Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One (2012) 1.11
The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci (2011) 1.10
The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis? Curr Opin Rheumatol (2014) 1.08
Complement, c1q, and c1q-related molecules regulate macrophage polarization. Front Immunol (2014) 1.06
Plasmacytoid dendritic cells and C1q differentially regulate inflammatory gene induction by lupus immune complexes. J Immunol (2011) 1.00
C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proc Natl Acad Sci U S A (2012) 0.99
Beyond apoptosis in lupus. Curr Opin Rheumatol (2014) 0.87
Requirements for innate immune pathways in environmentally induced autoimmunity. BMC Med (2013) 0.86
Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. J Exp Med (2016) 0.86
TLRs and interferons: a central paradigm in autoimmunity. Curr Opin Immunol (2013) 0.85
Fueling autoimmunity: type I interferon in autoimmune diseases. Expert Rev Clin Immunol (2013) 0.84
Possible novel biomarkers of organ involvement in systemic lupus erythematosus. Clin Rheumatol (2014) 0.83
C-reactive protein inhibits plasmacytoid dendritic cell interferon responses to autoantibody immune complexes. Arthritis Rheum (2013) 0.82
Suppression of Th1 cytokine production by a peptide derived from C4b. Inflamm Res (2013) 0.81
Genetics of SLE: functional relevance for monocytes/macrophages in disease. Clin Dev Immunol (2012) 0.81
C1q protein binds to the apoptotic nucleolus and causes C1 protease degradation of nucleolar proteins. J Biol Chem (2015) 0.81
Do follicular dendritic cells regulate lupus-specific B cells? Mol Immunol (2014) 0.80
Proteolytic inactivation of nuclear alarmin high-mobility group box 1 by complement protease C1s during apoptosis. Cell Death Discov (2016) 0.80
C1q-mediated repression of human monocytes is regulated by leukocyte-associated Ig-like receptor 1 (LAIR-1). Mol Med (2015) 0.79
Complement C4 maintains peripheral B-cell tolerance in a myeloid cell dependent manner. Eur J Immunol (2013) 0.79
Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. J Clin Immunol (2016) 0.79
Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside. Pediatr Rheumatol Online J (2014) 0.79
Pivotal Functions of Plasmacytoid Dendritic Cells in Systemic Autoimmune Pathogenesis. J Clin Cell Immunol (2014) 0.79
Inhibition of CXCL10 release by monomeric C3bi and C4b. Clin Exp Immunol (2012) 0.79
C1q rs292001 polymorphism and C1q antibodies in juvenile lupus and their relation to lupus nephritis. Clin Exp Immunol (2015) 0.78
Breakdown of Immune Tolerance in Systemic Lupus Erythematosus by Dendritic Cells. J Immunol Res (2016) 0.78
SLE-associated risk factors affect DC function. Immunol Rev (2016) 0.78
Uncoupling complement C1s activation from C1q binding in apoptotic cell phagocytosis and immunosuppressive capacity. Clin Immunol (2016) 0.78
Anti-DNA antibodies cross-react with C1q. J Autoimmun (2013) 0.76
C1q Modulates the Response to TLR7 Stimulation by Pristane-Primed Macrophages: Implications for Pristane-Induced Lupus. J Immunol (2016) 0.76
C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus. Front Immunol (2016) 0.75
The identification of a novel splicing mutation in C1qB in a Japanese family with C1q deficiency: a case report. Pediatr Rheumatol Online J (2013) 0.75
Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. J Mol Med (Berl) (2016) 0.75
Cause and consequences of the activated type I interferon system in SLE. J Mol Med (Berl) (2016) 0.75
Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression. Sci Rep (2017) 0.75
C1 Complex: An Adaptable Proteolytic Module for Complement and Non-Complement Functions. Front Immunol (2017) 0.75
TLR7/8 activation in neutrophils impairs immune complex phagocytosis through shedding of FcgRIIA. J Exp Med (2017) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry (1966) 15.12
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A (2003) 11.65
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 11.23
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol (2005) 7.74
Complement. Second of two parts. N Engl J Med (2001) 6.32
Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med (2005) 5.50
Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity (2006) 5.47
The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med (1997) 5.23
Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum (2005) 4.84
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
Delineating the genetic basis of systemic lupus erythematosus. Immunity (2001) 4.02
A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med (2000) 3.65
Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med (1991) 3.63
BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med (2001) 3.40
Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum (2006) 3.33
Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus (2000) 2.81
Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus. Clin Exp Immunol (1969) 2.81
Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A (2005) 2.73
Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med (1998) 2.69
The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol (2004) 2.67
Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med (2009) 2.63
Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol (2003) 2.45
Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum (1982) 2.40
Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol (2006) 2.11
C1q, autoimmunity and apoptosis. Immunobiology (2002) 1.94
C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol (2002) 1.88
Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum (2006) 1.86
Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol (1999) 1.78
Serum complement component levels in human glomerulonephritis. Ann Intern Med (1971) 1.70
C1q and systemic lupus erythematosus. Immunobiology (1998) 1.63
Physiological and pathological aspects of circulating immune complexes. Kidney Int (1989) 1.57
IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest (2008) 1.55
BDCA2/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol (2007) 1.49
Nature and functions of autoantibodies. Nat Clin Pract Rheumatol (2008) 1.43
Murine CD93 (C1qRp) contributes to the removal of apoptotic cells in vivo but is not required for C1q-mediated enhancement of phagocytosis. J Immunol (2004) 1.42
C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum (2009) 1.37
Innate immune functions of plasmacytoid dendritic cells. Curr Opin Immunol (2006) 1.35
C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes. Biochem J (1979) 1.28
Identification of types of cells in human peripheral blood that bind C1q. J Immunol (1981) 1.25
Murine low-density lipoprotein receptor-related protein 1 (LRP) is required for phagocytosis of targets bearing LRP ligands but is not required for C1q-triggered enhancement of phagocytosis. J Immunol (2008) 1.20
Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood (2004) 1.20
Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer. J Immunol Methods (2006) 1.17
Activation of the early components of the classical complement pathway under physiologic conditions. J Immunol (1981) 1.15
gC1q receptor ligation selectively down-regulates human IL-12 production through activation of the phosphoinositide 3-kinase pathway. J Immunol (2005) 1.15
Organization of the autoantibody repertoire in healthy newborns and adults revealed by system level informatics of antigen microarray data. Proc Natl Acad Sci U S A (2009) 1.14
Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol (2009) 1.11
Different isoforms of human FcRII distinguished by CDw32 antibodies. J Immunol (1990) 1.10
Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum (2009) 1.09
Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines. J Interferon Cytokine Res (2002) 1.09
Interferon and Aicardi-Goutières syndrome. Eur J Paediatr Neurol (2002) 1.07
Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization. J Clin Invest (1985) 1.04
Sequential studies of complement activation in systemic lupus erythematosus. Scand J Rheumatol (1985) 1.02
Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificity. J Exp Med (2005) 1.02
Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens (2003) 1.02
Genetic deficiency of C4, C2 or C1q and lupus syndromes. Association with anti-Ro (SS-A) antibodies. Clin Exp Immunol (1985) 1.00
Immune complex-mediated tissue injury: a multistep paradigm. Trends Immunol (2005) 0.99
Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol (2009) 0.97
Increased positive selection of B1 cells and reduced B cell tolerance to intracellular antigens in c1q-deficient mice. J Immunol (2007) 0.96
Autoantibodies to the collagen-like region of C1q are strongly associated with classical pathway-mediated hypocomplementemia in systemic lupus erythematosus. Lupus (1996) 0.95
Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells. Immunology (2006) 0.91
Immune complex processing in C1q-deficient mice. Clin Exp Immunol (2001) 0.90
Pediatric systemic lupus erythematosus with C1q deficiency. Ann N Y Acad Sci (2007) 0.88
Nitric oxide inhibits IFN-alpha production of human plasmacytoid dendritic cells partly via a guanosine 3',5'-cyclic monophosphate-dependent pathway. J Immunol (2005) 0.84
Clinical variability and characteristic autoantibody profile in primary C1q complement deficiency. Rheumatology (Oxford) (2007) 0.83
Activity of systemic lupus erythematosus in end-stage renal disease patients: study in a Brazilian cohort. Am J Nephrol (2005) 0.83
Expression and function of Fc gamma RII on human natural killer cells. Nat Immun (1995) 0.82
Reduced expression of C1q-mRNA in monocytes from patients with systemic lupus erythematosus. Clin Exp Immunol (2006) 0.81
Significance of low molecular weight C1q in systemic lupus erythematosus. Ann Rheum Dis (1990) 0.78
The human complement C1 complex has a picomolar dissociation constant at room temperature. J Immunol (1997) 0.78
Precision and functional specificity in mRNA decay. Proc Natl Acad Sci U S A (2002) 8.20
Genome-wide analysis of mRNA translation profiles in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (2003) 7.45
Histone variant H2A.Z marks the 5' ends of both active and inactive genes in euchromatin. Cell (2005) 7.20
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
Global nucleosome occupancy in yeast. Genome Biol (2004) 5.49
Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med (2010) 3.98
Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A (2002) 3.85
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell (2003) 3.66
Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity (2012) 3.49
Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc Natl Acad Sci U S A (2002) 3.28
Contrasting mechanisms of interferon-α inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists. Arthritis Rheum (2013) 3.20
Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells. Immunity (2004) 2.89
Quantitative measurement of nuclear translocation events using similarity analysis of multispectral cellular images obtained in flow. J Immunol Methods (2006) 2.78
B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med (2010) 2.42
Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) (2010) 2.26
Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med (2004) 2.25
Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling. Nat Immunol (2010) 2.07
Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology (2003) 2.00
The Stanford Tissue Microarray Database. Nucleic Acids Res (2007) 1.96
Cell cycle- and chaperone-mediated regulation of H3K56ac incorporation in yeast. PLoS Genet (2008) 1.93
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood (2013) 1.86
Distinguishing modes of cell death using the ImageStream multispectral imaging flow cytometer. Cytometry A (2004) 1.86
Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet (2011) 1.84
DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J Exp Med (2011) 1.79
Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum (2007) 1.77
Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood (2010) 1.75
Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet (2006) 1.74
Structure of the coiled-coil dimerization motif of Sir4 and its interaction with Sir3. Structure (2003) 1.71
Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J Immunol (2006) 1.69
Epigenome microarray platform for proteome-wide dissection of chromatin-signaling networks. PLoS One (2009) 1.66
IgM+IgD+CD27+ B cells are markedly reduced in IRAK-4-, MyD88-, and TIRAP- but not UNC-93B-deficient patients. Blood (2012) 1.65
Mature dendritic cells readily break tolerance in normal mice but do not lead to disease expression. Arthritis Rheum (2005) 1.63
I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med (2002) 1.63
Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood (2012) 1.62
Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.61
Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol (2002) 1.60
Prevalence, outcome and pre-hospital management of anaphylaxis by first aiders and paramedical ambulance staff in Manchester, UK. Resuscitation (2010) 1.53
Alu-repeat-induced deletions within the NCF2 gene causing p67-phox-deficient chronic granulomatous disease (CGD). Hum Mutat (2010) 1.49
Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Res Ther (2012) 1.49
Dichotomous response to transforming growth factor β after T cell receptor activation by naive CD4+ T cells from DBA/1 mice: enhanced retinoic acid receptor-related orphan nuclear receptor γt expression yet reduced FoxP3 expression. Arthritis Rheum (2011) 1.45
Systematic dissection of roles for chromatin regulators in a yeast stress response. PLoS Biol (2012) 1.44
Temporal dissection of T-bet functions. J Immunol (2007) 1.43
A nonhistone protein-protein interaction required for assembly of the SIR complex and silent chromatin. Mol Cell Biol (2005) 1.42
Innate and adaptive immune response to apoptotic cells. J Autoimmun (2007) 1.42
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood (2011) 1.41
Sensitivity measurement and compensation in spectral imaging. Cytometry A (2006) 1.41
IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity (2005) 1.40
X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood (2010) 1.40
Factors determining the effectiveness of oral ciclosporin in the treatment of severe childhood atopic dermatitis. J Dermatolog Treat (2012) 1.39
Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum (2008) 1.38
Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway. Proc Natl Acad Sci U S A (2004) 1.38
Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol (2010) 1.36
Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol (2006) 1.34
IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. J Immunol (2009) 1.33
Plasmonic substrates for multiplexed protein microarrays with femtomolar sensitivity and broad dynamic range. Nat Commun (2011) 1.30
Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol (2012) 1.30
Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest (2010) 1.27
Haptoglobin is synthesized during granulocyte differentiation, stored in specific granules, and released by neutrophils in response to activation. Blood (2006) 1.27
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab (2008) 1.26
Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.25
Interferon regulatory factor 7-mediated responses are defective in cord blood plasmacytoid dendritic cells. Eur J Immunol (2008) 1.24
Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro. J Immunol (2010) 1.24
Receptor cross-linking on human plasmacytoid dendritic cells leads to the regulation of IFN-alpha production. J Immunol (2006) 1.24
The use of chromatin immunoprecipitation assays in genome-wide analyses of histone modifications. Methods Enzymol (2004) 1.23
STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS One (2011) 1.22
A costimulation-initiated signaling pathway regulates NFATc1 transcription in T lymphocytes. J Immunol (2007) 1.21
Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum (2008) 1.21
SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood (2004) 1.21
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther (2010) 1.18
DOCK8 is critical for the survival and function of NKT cells. Blood (2013) 1.17
RNA polymerase mapping during stress responses reveals widespread nonproductive transcription in yeast. Genome Biol (2010) 1.17
On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions. Nat Med (2012) 1.17
Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer. J Immunol Methods (2006) 1.17
Retracted Autoimmunity as the consequence of a spontaneous mutation in Rasgrp1. Immunity (2003) 1.15
Opsonization of apoptotic cells and its effect on macrophage and T cell immune responses. Ann N Y Acad Sci (2003) 1.13
Clinical features that identify children with primary immunodeficiency diseases. Pediatrics (2011) 1.13
Intracellular mammalian DNA stimulates myeloid dendritic cells to produce type I interferons predominantly through a toll-like receptor 9-independent pathway. Arthritis Rheum (2006) 1.13
Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol (2004) 1.12
The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol Immunol (2005) 1.11
Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol (2009) 1.11
Autoimmunity in MFG-E8-deficient mice is associated with altered trafficking and enhanced cross-presentation of apoptotic cell antigens. J Clin Invest (2011) 1.11
Necessary role of phosphatidylinositol 3-kinase in transforming growth factor beta-mediated activation of Akt in normal and rheumatoid arthritis synovial fibroblasts. Arthritis Rheum (2002) 1.11
IFN-alpha is not sufficient to drive Th1 development due to lack of stable T-bet expression. J Immunol (2007) 1.10
Cutting edge: Type I IFN drives emergency myelopoiesis and peripheral myeloid expansion during chronic TLR7 signaling. J Immunol (2013) 1.08
Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells. J Exp Med (2013) 1.07
Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol (2003) 1.07
Domain structure and protein interactions of the silent information regulator Sir3 revealed by screening a nested deletion library of protein fragments. J Biol Chem (2006) 1.07
Extended depth of field imaging for high speed cell analysis. Cytometry A (2007) 1.06
Role of complement and other innate immune mechanisms in the removal of apoptotic cells. Curr Dir Autoimmun (2006) 1.06
Ly6C(low) monocytes differentiate into dendritic cells and cross-tolerize T cells through PDL-1. J Immunol (2009) 1.06
Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center. J Allergy Clin Immunol (2008) 1.04